SynthesisFrontiers in medicine2026
Efficacy and safety of oral Chinese patent medicine combined with quadruple therapy for chronic atrophic gastritis: a systematic review and network meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic atrophic gastritis (CAG) is an important precancerous lesion of gastric cancer, with Methods: Randomized controlled trials (RCTs) on oral Chinese patent medicines combined with quadruple therapy for chronic atrophic gastritis were searched electronically in databases including China National Knowledge Infrastructure (CNKI), VIP, WanFang, Chinese Biomedical Literature Database (CBM), PubMed, Web of Science, and Cochrane Library from January 1, 2016, to April 1, 2026. Network Meta-analysis was performed on the included RCTs using Stata and R software. Results: A total of 45 RCTs were included, involving 4,465 participants and 10 kinds of oral Chinese patent medicines. The network Meta-analysis showed that the 10 oral Chinese patent medicines (OCPMs) combined with quadruple therapy (QT) could effectively eradicate Conclusion: Within the limitations of low-certainty evidence, the 10 oral Chinese patent medicines combined with quadruple therapy showed exploratory trends in improving Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261366962, CRD420261366962.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.